Literature DB >> 25355275

Antibiotic resistance management.

Andrew F Read1, Robert J Woods2.   

Abstract

Entities:  

Year:  2014        PMID: 25355275      PMCID: PMC4228198          DOI: 10.1093/emph/eou024

Source DB:  PubMed          Journal:  Evol Med Public Health        ISSN: 2050-6201


× No keyword cloud information.

Antibiotic resistance

Antibiotic resistance is ‘bacteria changing in ways that reduce or eliminate the effectiveness of antibiotics’ [1]. These changes are due to bacterial evolution, and threaten the single greatest therapeutic advance in the history of medicine. Antibiotic resistance genes arose long ago in response to naturally occurring antibiotics. Modern medicine has driven further evolution of some of these genes. Resistance can also arise spontaneously by mutation. In bacteria, genes can be inherited or they can be acquired from non-relatives on mobile genetic elements like plasmids. This horizontal gene transfer (HGT) can occur between very different bacteria. Antibiotic use drives the evolution of resistance [2]. Resistant bacteria spread by natural selection when antibiotics fail to halt their reproduction while removing their drug-sensitive competitors. Antibiotic resistance management is an attempt to slow the spread of resistance by the judicious use of antibiotics, an important aim of antibiotic stewardship programs.

Evolutionary perspectives

One way the evolution of antibiotic resistance can be slowed is by minimizing the strength of natural selection for resistance genes. This means reducing antibiotic use. Don’t treat asymptomatic infections. Use antibiotics only where they can work. 70% of acute bronchitis cases are treated with antibiotics to no effect [3]. When treatment is necessary, use as little as possible. Decrease the need for antibiotic treatment with vaccines, hygiene, and isolation of infected patients. Prevent non-medical uses like growth promotion in farm animals. Reducing antibiotic use also limits selection for resistance in harmless bacteria that can donate genes to pathogens by HGT, as does targeting pathogens with narrow spectrum antibiotics. Another way to slow resistance evolution is to prevent pathogens acquiring resistance genes in the first place. In some cases, this can be done with high doses (dead bugs can’t evolve) or combination therapy (acquiring resistance to several drugs at once is unlikely). Bottom line: antibiotics should be used only when necessary and then, appropriately.

Future clinical implications

What constitutes appropriate use of antibiotics can be controversial. For instance, dead bugs can’t acquire resistance, so aggressively killing pathogenic bacteria with antibiotics can retard resistance evolution. But aggressive treatment also maximizes the evolutionary advantage of already resistant pathogens or of non-target bacteria that can be a source of resistance genes. Consequently, treatments designed to minimize the rate of resistance acquisition might not be best when resistance is already present [4]. Other major research questions: (i) when do drug cocktails select for multidrug resistance faster than sequential monotherapies?, (ii) does repeated antibiotic use generate a microbiomic reservoir of resistance genes for future pathogens?, (iii) what properties of particular drugs make them more evolution-proof than others?, and (iv) is inappropriate antibiotic use the main evolutionary force undermining drug efficacy—or is it medically appropriate use?
  3 in total

1.  The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy.

Authors:  Andrew F Read; Troy Day; Silvie Huijben
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

Review 2.  Population biological principles of drug-resistance evolution in infectious diseases.

Authors:  Pia Abel zur Wiesch; Roger Kouyos; Jan Engelstädter; Roland R Regoes; Sebastian Bonhoeffer
Journal:  Lancet Infect Dis       Date:  2011-03       Impact factor: 25.071

3.  Antibiotic prescribing for adults with acute bronchitis in the United States, 1996-2010.

Authors:  Michael L Barnett; Jeffrey A Linder
Journal:  JAMA       Date:  2014-05-21       Impact factor: 56.272

  3 in total
  44 in total

1.  The antibiotic resistance crisis: part 1: causes and threats.

Authors:  C Lee Ventola
Journal:  P T       Date:  2015-04

2.  Epidemiology, Bacteriological Profile, and Antibiotic Sensitivity Pattern of Burn Wounds in the Burn Unit of a Tertiary Care Hospital.

Authors:  Noman A Chaudhary; Muhammad D Munawar; Muhammad T Khan; Kausar Rehan; Abdullah Sadiq; Ahsan Tameez-Ud-Din; Hamza Waqar Bhatti; Zuhair Ali Rizvi
Journal:  Cureus       Date:  2019-06-01

3.  Direct detection of intact Klebsiella pneumoniae carbapenemase variants from cell lysates: Identification, characterization and clinical implications.

Authors:  William M McGee; Matthew L Faron; Jason R Neil; Scott R Kronewitter; Blake W Buchan; Nathan A Ledeboer; James L Stephenson
Journal:  Clin Mass Spectrom       Date:  2020-07-18

4.  Imipenem Resistance in Gram-Negative Bacteria in the Central Pediatric Teaching Hospital in Baghdad, Iraq.

Authors:  H Sahib Abdul-Mohammed; A Kamal Mohammed; Z Mohsen Ahmed
Journal:  Arch Razi Inst       Date:  2022-02-28

5.  Controlling Antimicrobial Activity of Quinolones Using Visible/NIR Light-Activated BODIPY Photocages.

Authors:  Elena Contreras-García; Carmen Lozano; Cristina García-Iriepa; Marco Marazzi; Arthur H Winter; Carmen Torres; Diego Sampedro
Journal:  Pharmaceutics       Date:  2022-05-17       Impact factor: 6.525

Review 6.  An evolutionary mismatch narrative to improve lifestyle medicine: a patient education hypothesis.

Authors:  Anthony J Basile; Michael W Renner; Brandon H Hidaka; Karen L Sweazea
Journal:  Evol Med Public Health       Date:  2021-02-24

Review 7.  Alzheimer's disease and symbiotic microbiota: an evolutionary medicine perspective.

Authors:  Molly Fox; Delaney A Knorr; Kacey M Haptonstall
Journal:  Ann N Y Acad Sci       Date:  2019-06-10       Impact factor: 6.499

8.  Phenotypical resistance correlation networks for 10 non-typhoidal Salmonella subpopulations in an active antimicrobial surveillance programme.

Authors:  W J Love; K A Zawack; J G Booth; Y T Gröhn; C Lanzas
Journal:  Epidemiol Infect       Date:  2018-04-30       Impact factor: 4.434

9.  Consultations and antibiotic treatment for urinary tract infections in Norwegian primary care 2006-2015, a registry-based study.

Authors:  Lars Emil Aga Haugom; Sabine Ruths; Knut Erik Emberland; Knut Eirik Ringheim Eliassen; Guri Rortveit; Knut-Arne Wensaas
Journal:  BMC Fam Pract       Date:  2021-06-24       Impact factor: 2.497

10.  Molecular epidemiology of carbapenem-resistance plasmids using publicly available sequences.

Authors:  Galen E Card; Brandon D Pickett; Perry G Ridge; Richard A Robison
Journal:  Genome       Date:  2019-09-06       Impact factor: 2.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.